GM potatoes and the implications for pharma
This article was originally published in Scrip
Genetically modified potatoes might not appear at first sight to be a matter of more than passing interest to observers of the pharmaceutical scene. But the European Commission's go-ahead this week for cultivation of the first GM potato – also the first GMO authorisation in the EU since 1998 – has a number of implications for pharma firms working in Europe.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.